Racial/Ethnic Disparities in Telemedicine Utilization and Satisfaction Among Breast Cancer Patients During the COVID-19 Pandemic: A Mixed-Methods Analysis.
Racial/Ethnic Disparities in Telemedicine Utilization and Satisfaction Among Breast Cancer Patients During the COVID-19 Pandemic: A Mixed-Methods Analysis. Telemed J E Health. 2023 Sep 07.
PMID: 37676974
Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer.
Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer. Magn Reson Imaging. 2023 Aug 21; 104:9-15.
PMID: 37611646
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 Aug 15; 29(16):3101-3109.
PMID: 37195235
Stress, Isolation, and Sleep Quality among Breast Cancer Survivors throughout the COVID-19 Pandemic: A Longitudinal Study in a Multi-Ethnic Cohort.
Stress, Isolation, and Sleep Quality among Breast Cancer Survivors throughout the COVID-19 Pandemic: A Longitudinal Study in a Multi-Ethnic Cohort. Res Sq. 2023 Aug 10.
PMID: 37609132
Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.
Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 2023 05 25; 25(1):58.
PMID: 37231433
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients.
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients. NPJ Breast Cancer. 2023 May 06; 9(1):33.
PMID: 37149628
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023 06 12; 41(6):1091-1102.e4.
PMID: 37146605
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer.
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer. Breast Cancer Res Treat. 2023 Jul; 200(1):75-83.
PMID: 37120458
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence.
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence. NPJ Breast Cancer. 2023 Apr 14; 9(1):25.
PMID: 37059742
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database.
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023 04 01; 9(4):500-510.
PMID: 36821125